BOOSTER DOSE! Govt APPROVES Bharat Biotech's Covaxin vaccine manufacturing facility in Gujarat

In order to speed up the free vaccination drive, the government on August 10 approved a vaccine manufacturing facility for the production of Bharat Biotech's Covaxin in Ankleshwar, Gujarat. 

Union Minister of Health and Family Welfare Mansukh Mandaviya took to Twitter to inform this. He said also this drive will increase the vaccine availability and accelerate the world’s largest vaccine drive.

See Zee Business Live TV Streaming Below:

He tweeted: “Govt of India approves vaccine manufacturing facility for production of @BharatBiotech's #Covaxin in Ankleshwar, Gujarat. Following PM @NarendraModiji's vision of #SabkoVaccineMuftVaccine, this will increase vaccine availability & accelerate the world’s largest vaccine drive.” 

Covaxin, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).

Govt of India approves vaccine manufacturing facility for production of @BharatBiotech's #Covaxin in Ankleshwar, Gujarat.

Following PM @NarendraModi ji's vision of #SabkoVaccineMuftVaccine, this will increase vaccine availability & accelerate the world’s largest vaccine drive.

— Mansukh Mandaviya (@mansukhmandviya) August 10, 2021

The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility, according to the company’s website. 

The vaccine is developed using Whole-Virion Inactivated Vero Cell-derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection. 

Why develop Inactivated Vaccine? Conventionally, inactivated vaccines have been around for decades. Numerous vaccines for diseases such as Seasonal Influenza, Polio, Pertussis, Rabies, and Japanese Encephalitis use the same technology to develop inactivated vaccines with a safe track record of >300 million doses of supplies to date. It is the well-established, and time-tested platform in the world of vaccine technology.